Paper Details

  1. Home
  2. Paper Details

Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.

Author: GaoShun, GongGuotao, GuoXuanZhu, LiSijie, LinSheng, LuoYuyao, TangXuemei, ZhangYan, ZhangZhe

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

The toxicity profiles of six ALK-TKIs differed significantly. Alectinib might be the safest ALK-TKI drug based on the combined evidence of grades 3-4 AEs and the combined incidence.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) are new treatment for advanced non-small cell lung cancer. Here, we quantified the toxicity profiles of different ALK-TKIs to guide clinical decision making. MATERIALS AND METHODS: We searched PubMed, Embase, and the Cochra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.lungcan.2023.107319

データ提供：米国国立医学図書館（NLM）

Comparing the Safety of ALK-TKIs for Advanced Lung Cancer: A Network Meta-Analysis

Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) are a new treatment option for advanced non-small cell lung cancer. This systematic review and network meta-analysis aimed to compare the toxicity profiles of different ALK-TKIs, providing valuable information for clinicians to make informed treatment decisions. The study analyzed data from 13 randomized controlled trials (RCTs) involving 3,353 patients, providing a robust evidence base for this comparison.

Toxicity Profiles of ALK-TKIs: A Detailed Analysis

The network meta-analysis revealed that the toxicity profiles of different ALK-TKIs varied significantly, highlighting the importance of individualized treatment considerations based on patient characteristics and specific side effects. The study also identified alectinib as potentially the safest option based on the combined evidence of grade 3-4 adverse events and overall incidence.

Navigating the Desert of Treatment Options

This research provides valuable insights for healthcare professionals treating advanced non-small cell lung cancer. It's like navigating a desert, where understanding the nuances of each ALK-TKI is crucial for selecting the most appropriate treatment option for individual patients. The study's findings can help clinicians make informed decisions to optimize treatment outcomes and minimize potential adverse effects.

Dr.Camel's Conclusion

This study is a valuable resource for clinicians, offering a comprehensive analysis of the toxicity profiles of various ALK-TKIs. It's like having a map guiding you through the desert of treatment options, helping you navigate the challenges and make informed decisions for your patients.

Date :
  1. Date Completed 2023-09-19
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

37597303

DOI: Digital Object Identifier

10.1016/j.lungcan.2023.107319

Related Literature

Article Analysis
・Effects of ceritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.